Cancer Immunotherapy and the Immune Response in Follicular Lymphoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer Immunotherapy and the Immune Response in Follicular Lymphoma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-06-19
DOI
10.3389/fonc.2018.00219
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma
- (2018) Stefano Luminari et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?
- (2017) Mehdi Hamadani et al. Journal of Oncology Practice
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- What is the optimal management of early-stage low-grade follicular lymphoma in the modern era?
- (2015) John A. Vargo et al. CANCER
- 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial
- (2014) Peter J Hoskin et al. LANCET ONCOLOGY
- Afucosylated Antibodies Increase Activation of Fc RIIIa-Dependent Signaling Components to Intensify Processes Promoting ADCC
- (2014) S. D. Liu et al. Cancer Immunology Research
- Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource
- (2013) Brian K. Link et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma
- (2012) Zhi-Zhang Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation
- (2010) Thomas J. Pugh et al. CANCER
- Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98
- (2010) Giovanni Martinelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling
- (2008) R. J. Byers et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now